Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 29;149(4):1242–1252.e12. doi: 10.1016/j.jaci.2022.01.013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig 1 — SARS-CoV-2 antibody titer analysis using sera from fully vaccinated (ChAdOx1, BNT162b2, or mRNA-1273) or convalescent participants. A, Individual IgG antibody titer analysis against SARS-CoV-2-S1 domain for individuals fully vaccinated with ChAdOx1 (n = 33), BNT162b2 (n = 31), or mRNA-1273 (n = 23) and of convalescent patients (n = 29) were assessed with the anti–SARS-CoV-2 QuantiVac ELISA (IgG) kit. Results are presented as binding antibody unit per milliliter of serum (BAU∙mL⁻¹). Corresponding percentages of participants and patients with positive, borderline, or negative IgG antibodies against SARS-CoV-2-S1 are visualized in the graph.B, Individual IgA antibody titer analysis against SARS-CoV-2-S1 domain for fully vaccinated and convalescent participants was performed with the anti–SARS-CoV-2-ELISA (IgA) kit. Results are presented as RoA. Corresponding percentages of participants with positive, borderline, or negative IgA antibodies against SARS-CoV-2-S1 are visualized in the graph.C, Individual total Ig antibody titer analysis against SARS-CoV-2 RBD for participants fully vaccinated and convalescent individuals was performed with the Wantai SARS-CoV-2 Ab ELISA kit. Results are presented as RoA. Corresponding percentages of participants with positive, borderline, or negative total Ig against SARS-CoV-2-S1 are visualized in the graph. Statistical significance between the 4 groups was determined by Mann-Whitney U test for nonparametric distribution (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). Medians are visualized as red lines together with the interquartile range as error bar. Cutoff values are illustrated by the gray dashed line.